RPL39C Antibody

What is RPL39 protein and what role does it play in cellular function?

RPL39 (ribosomal protein L39) is a 6 kDa protein component of the 60S ribosomal subunit in eukaryotes, specifically identified as part of the large ribosomal subunit protein eL39 family . As an integral component of the ribosomal machinery, RPL39 participates in protein synthesis by contributing to ribosomal structure and function. The protein consists of approximately 50 amino acids and is highly conserved across species, indicating its evolutionary importance in translational processes. Recent research has begun to uncover potential extraribosomal functions of RPL39, including roles in cellular stress responses and potential implications in certain pathological conditions, though these functions require further investigation in specific experimental contexts.

What types of RPL39 antibodies are available for research applications?

Multiple validated RPL39 antibodies are available for research use, with different specifications and applications:

These antibodies have been validated through multiple experimental approaches including Western blot analysis with specific cells, immunohistochemical staining of various tissues, and immunofluorescence applications, ensuring their specificity and utility across different research contexts.

How do I determine the appropriate storage conditions for RPL39 antibodies?

RPL39 antibodies require specific storage conditions to maintain their functionality and specificity. Based on manufacturer recommendations, these antibodies should be stored at -20°C for long-term preservation, where they remain stable for approximately one year after shipment . For short-term storage and frequent use, storage at 4°C for up to one month is acceptable, but repeated freeze-thaw cycles should be avoided as they can compromise antibody integrity and performance . Most commercial RPL39 antibodies are provided in a stabilizing buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain antibody structure and function . For antibodies supplied in smaller volumes (20μl), manufacturers often include 0.1% BSA as an additional stabilizing agent . Proper aliquoting upon receipt is recommended for antibodies that will be used multiple times to minimize freeze-thaw cycles, though some formulations specifically note that "aliquoting is unnecessary for -20°C storage" .

What are the recommended dilutions for different applications of RPL39 antibodies?

Optimal antibody dilutions vary significantly depending on the experimental application, sample type, and specific antibody being used. The following table provides recommended starting dilutions for common applications of RPL39 antibodies:

It is strongly recommended to titrate each antibody in your specific experimental system to determine optimal working concentrations, as the actual effective dilution may vary based on sample type, detection method, and experimental conditions . Researchers should perform preliminary experiments with concentration gradients to establish the optimal signal-to-noise ratio for their particular application and sample type.

What antigen retrieval methods should be used for RPL39 antibody in immunohistochemistry applications?

For optimal immunohistochemical detection using RPL39 antibodies, specific antigen retrieval methods have been validated and recommended. When using antibody 14990-1-AP for IHC applications, the primary suggested method is heat-induced epitope retrieval using TE buffer at pH 9.0 . This alkaline condition helps to break protein cross-links formed during tissue fixation, thereby improving antigen accessibility. Alternatively, citrate buffer at pH 6.0 can be used as a secondary option for antigen retrieval with this antibody . For antibodies A10219-1 and A10219S39, specific validation has been performed on paraffin-embedded human tissue samples, including brain and colorectal carcinoma tissue, respectively . While the exact retrieval conditions for these antibodies are not specified in detail, the successful IHC staining demonstrates their compatibility with standard paraffin-embedded tissue processing methods. Researchers should note that optimization of antigen retrieval methods may be necessary depending on the tissue type, fixation time, and age of paraffin blocks.

What positive controls are recommended for validating RPL39 antibody specificity?

Selecting appropriate positive controls is crucial for validating antibody specificity and experimental protocols. For RPL39 antibodies, several validated positive controls have been experimentally determined:

When establishing a new experimental system, researchers should first replicate these validated controls to confirm their antibody is functioning as expected before proceeding to experimental samples. Additionally, inclusion of negative controls (such as isotype controls or secondary antibody-only controls) is essential for distinguishing specific from non-specific signals. For definitive validation, researchers working with genetically tractable systems may consider using RPL39 knockdown or knockout samples, as multiple publications have successfully utilized these approaches with the available antibodies .

How can RPL39 antibodies be effectively used in cancer research applications?

RPL39 antibodies have demonstrated utility in cancer research, particularly in studies involving liver cancer and colorectal carcinoma. Immunohistochemical analyses using these antibodies have successfully detected RPL39 in human liver cancer tissue and colorectal carcinoma samples, making them valuable tools for examining ribosomal protein expression patterns in neoplastic tissues . When designing experiments to investigate RPL39 in cancer contexts, researchers should consider:

• Expression pattern analysis: RPL39 antibodies can be used to compare expression patterns between normal and cancerous tissues using IHC or Western blot techniques. Published validation has confirmed detection in human liver cancer tissue with suggested antigen retrieval using TE buffer pH 9.0 .

• Subcellular localization studies: Immunofluorescence applications using RPL39 antibodies (dilution 1:200-1:1000) can reveal changes in the subcellular distribution of RPL39 in cancer cells compared to normal cells .

• Functional studies: Several publications have successfully used RPL39 antibodies in knockdown/knockout experimental designs, allowing researchers to investigate the functional consequences of RPL39 depletion in cancer models .

• Correlation studies: IHC staining of tissue microarrays using validated RPL39 antibodies (such as A10219S39 at 1:50-1:200 dilution) can facilitate correlation analyses between RPL39 expression levels and clinicopathological parameters or patient outcomes .

For robust results in cancer research applications, it is advisable to validate findings using multiple antibodies and complementary techniques, such as combining protein detection with mRNA expression analysis.

What approaches can be used to troubleshoot inconsistent or unexpected results when using RPL39 antibodies?

When encountering unexpected or inconsistent results with RPL39 antibodies, systematic troubleshooting approaches should be implemented:

• Verify antibody integrity: Check storage conditions and antibody expiration date. Improper storage (repeated freeze-thaw cycles) can compromise antibody function. RPL39 antibodies should be stored at -20°C for long-term storage or 4°C for up to one month for frequent use .

• Optimize protein extraction: For Western blot applications, ensure complete protein extraction using appropriate lysis buffers. The small size of RPL39 (6 kDa) may require special considerations for protein extraction and gel separation protocols .

• Adjust antigen retrieval conditions: For IHC applications showing weak or absent signal, modify antigen retrieval methods. For antibody 14990-1-AP, try alternating between the recommended TE buffer (pH 9.0) and citrate buffer (pH 6.0) .

• Titrate antibody concentration: Unexpected results often reflect suboptimal antibody concentration. Perform a dilution series spanning the recommended range (e.g., WB: 1:500-1:2000; IHC: 1:20-1:200) to identify optimal working dilution for your specific samples .

• Include appropriate controls: Always run positive controls (e.g., HepG2 cells, human liver tissue) and negative controls (secondary antibody only, isotype controls) in parallel with experimental samples .

• Consider sample-dependent variations: The antibody manufacturers note that results can be "sample-dependent," necessitating optimization for each experimental system .

• Verify specificity using genetic approaches: For definitive validation of unexpected results, consider using RPL39 knockdown/knockout samples, as multiple publications have successfully utilized these approaches with the available antibodies .

If inconsistencies persist after these troubleshooting steps, consulting the antibody manufacturer's technical support team is recommended.

How can RPL39 knockdown/knockout validation be effectively performed using these antibodies?

Validating RPL39 knockdown or knockout models requires careful experimental design and appropriate controls. Based on the search results, multiple publications have successfully used RPL39 antibodies in knockdown/knockout (KD/KO) experimental designs . While specific protocols are not detailed in the search results, the following methodological approach is recommended based on standard practices:

• Experimental design:

  • Generate RPL39 knockdown using siRNA/shRNA approaches or knockout using CRISPR-Cas9 technology

  • Include appropriate controls: non-targeting siRNA/shRNA, wild-type cells, or CRISPR negative controls

  • Collect samples at optimal timepoints post-transfection/transduction (typically 48-72 hours for siRNA, 5-7 days for shRNA)

• Validation using Western blot:

  • Prepare protein lysates from control and KD/KO samples

  • Use RPL39 antibody 14990-1-AP or A10219-1 at 1:500-1:2000 dilution

  • Include loading controls (e.g., β-actin, GAPDH)

  • Quantify band intensity using densitometry to determine knockdown efficiency

• Secondary validation methods:

  • Perform immunofluorescence staining (IF) using RPL39 antibody at 1:200-1:800 dilution to visualize reduced or absent protein expression

  • Consider flow cytometry (FC) as an alternative quantitative approach, as one publication has demonstrated successful use of RPL39 antibody in FC applications

  • Complement protein detection with mRNA expression analysis (RT-qPCR)

• Special considerations for RPL39:

  • When performing Western blot analysis, use appropriate gel systems for resolving low molecular weight proteins (6 kDa)

  • Consider using HepG2 cells as a positive control, as they have been validated for RPL39 antibody reactivity

  • Be aware that complete knockout of essential ribosomal proteins may be lethal, potentially necessitating inducible or conditional systems

By systematically implementing these approaches, researchers can confidently validate RPL39 knockdown or knockout models using the available antibodies.

How do I interpret unexpected band patterns in Western blots with RPL39 antibodies?

When analyzing Western blot results with RPL39 antibodies, researchers may occasionally observe unexpected band patterns that require careful interpretation:

• Expected band patterns: RPL39 has a calculated molecular weight of 6 kDa, and this corresponds to the observed molecular weight in validated Western blot experiments . In properly executed Western blots using validated positive controls (HepG2 cells, human liver tissue), a distinct band at approximately 6 kDa should be visible .

• Multiple bands or higher molecular weight bands: These may indicate:

  • Post-translational modifications of RPL39 (phosphorylation, ubiquitination)

  • Protein complexes that were not fully denatured

  • Cross-reactivity with related ribosomal proteins

  • Alternatively spliced variants

• Lower molecular weight bands: These might represent:

  • Degradation products

  • Proteolytic cleavage during sample preparation

  • Premature translation termination

• No visible bands: This could result from:

  • Insufficient protein loading

  • Ineffective protein transfer (particularly likely with small proteins like RPL39)

  • Sample degradation

  • Suboptimal antibody dilution

• Validation approaches for unexpected patterns:

  • Compare results with multiple RPL39 antibodies targeting different epitopes

  • Include positive controls (HepG2 cells) alongside experimental samples

  • Perform peptide competition assays to confirm specificity

  • Consider mass spectrometry for definitive identification of unexpected bands

Researchers should note that the small size of RPL39 (6 kDa) presents technical challenges for standard Western blot protocols. Special attention to gel percentage (15-20% preferred), transfer conditions (longer transfer times may be necessary), and membrane selection (PVDF membranes with smaller pore sizes may better retain small proteins) can improve detection specificity and reduce unexpected band patterns.

What factors should be considered when comparing results obtained with different RPL39 antibodies?

When comparing experimental results obtained using different RPL39 antibodies, several important factors should be considered to ensure accurate interpretation:

• Epitope differences: The three antibodies in the search results target different epitopes of the RPL39 protein:

  • 14990-1-AP uses an RPL39 fusion protein as immunogen

  • A10219-1 was raised against a synthesized peptide from human RPL39 (AA range: 1-50)

  • A10219S39 specifically targets the N-terminal region of Human RPL39
    These epitope differences may result in varying detection sensitivities, especially if the target region undergoes post-translational modifications or is involved in protein-protein interactions.

• Validated applications: Not all antibodies are validated for the same applications:

  • 14990-1-AP is validated for WB, IHC, IF/ICC, IP, and ELISA

  • A10219-1 is validated for ELISA, IF, IHC, and WB

  • A10219S39 is specifically validated for IHC applications only
    Comparing results across different applications should account for these validation differences.

• Species reactivity: While all three antibodies react with human samples, their cross-reactivity with other species varies:

  • 14990-1-AP has cited reactivity with human, mouse, and zebrafish

  • A10219-1 and A10219S39 are reactive to human, mouse, and rat
    When working with non-human samples, these reactivity differences could explain discrepant results.

• Optimal working dilutions: Each antibody has specific recommended dilution ranges for different applications, which may influence sensitivity and background:

  • For Western blot: both 14990-1-AP and A10219-1 recommend 1:500-1:2000

  • For IHC: 14990-1-AP (1:20-1:200), A10219-1 (1:100-1:300), and A10219S39 (1:50-1:200)

• Validation controls: When comparing results, consider whether the same positive controls were used for validation:

  • 14990-1-AP was validated in HepG2 cells and human liver tissue

  • A10219-1 was validated in human brain tissue

  • A10219S39 was validated in human colorectal carcinoma tissue

By systematically accounting for these variables, researchers can more accurately interpret differences in results obtained with different RPL39 antibodies and determine whether discrepancies reflect technical variables or biologically meaningful phenomena.

What special considerations should be made when using RPL39 antibodies for co-immunoprecipitation studies?

When designing co-immunoprecipitation (co-IP) experiments to study RPL39 protein interactions, several critical methodological considerations should be addressed:

• Antibody selection: Among the RPL39 antibodies in the search results, 14990-1-AP has been specifically validated for immunoprecipitation (IP) applications, with at least one publication confirming its utility . This makes it the preferred choice for co-IP studies involving RPL39.

• Lysis buffer optimization: Given RPL39's role as a ribosomal protein, it exists in stable ribonucleoprotein complexes. Lysis buffer composition significantly impacts co-IP success:

  • For studying core ribosomal interactions: Use mild lysis conditions (150-300 mM NaCl, 0.5-1% NP-40 or Triton X-100)

  • For detecting weaker or transient interactions: Reduce salt concentration (100-150 mM NaCl) and detergent percentage (0.1-0.5%)

  • Consider including RNase inhibitors if RNA-dependent interactions are being investigated

• Control experiments: Implement rigorous controls specific to RPL39 co-IP:

  • Include IgG control from the same species (rabbit) as the RPL39 antibody

  • Perform reverse co-IP when possible (immunoprecipitate with antibody against potential interacting partner and probe for RPL39)

  • Consider using RPL39 knockdown/knockout samples as specificity controls, as publications have validated these approaches

• Detection challenges: The small size of RPL39 (6 kDa) presents technical challenges:

  • Use gradient or high percentage (15-20%) gels for adequate resolution

  • Be aware that the RPL39 band may be masked by antibody light chains (~25 kDa) in conventional IP-Western blot analyses

  • Consider using specialized secondary antibodies that don't recognize denatured IgG or conjugating RPL39 antibody directly to beads

• Cross-linking considerations: For detecting transient interactions, mild formaldehyde cross-linking (0.1-0.5%) prior to lysis can be employed, but this requires careful optimization to avoid over-cross-linking.

By addressing these methodological considerations, researchers can optimize co-IP experiments to successfully investigate RPL39's protein interaction network and potential extraribosomal functions.

How can RPL39 antibodies be effectively used in tissue microarray (TMA) applications?

Utilizing RPL39 antibodies in tissue microarray (TMA) applications requires specialized methodological approaches to ensure consistent, reliable, and interpretable results across multiple tissue samples:

• Antibody selection and validation: Based on the search results, both 14990-1-AP and A10219S39 antibodies have been validated for immunohistochemistry applications on paraffin-embedded tissues, making them suitable candidates for TMA studies :

  • 14990-1-AP has been validated on human liver cancer tissue

  • A10219S39 has been validated on human colorectal carcinoma tissue

• Optimized IHC protocol for TMA applications:

  • Antigen retrieval: For 14990-1-AP, use TE buffer at pH 9.0 as the primary method, with citrate buffer at pH 6.0 as an alternative

  • Antibody dilution: Start with the mid-range of recommended dilutions (14990-1-AP: 1:100; A10219S39: 1:100) and optimize based on initial results

  • Incubation conditions: Overnight incubation at 4°C often provides optimal sensitivity and specificity for TMAs

  • Detection system: Use highly sensitive detection systems (polymer-based or tyramide signal amplification) to accommodate the range of RPL39 expression across different tissues

• TMA-specific considerations for RPL39 detection:

  • Include validated positive controls (human liver tissue, human colorectal carcinoma) on each TMA slide

  • Incorporate negative controls (isotype control or secondary antibody only) in the TMA design

  • Due to potential heterogeneity in RPL39 expression, consider using duplicate or triplicate cores per sample

  • Include normal tissue counterparts for comparative analysis

• Scoring and interpretation guidelines:

  • Develop a standardized scoring system for RPL39 immunoreactivity (intensity and percentage of positive cells)

  • Consider digital image analysis for objective quantification of staining intensity and distribution

  • Record subcellular localization patterns (expected to be primarily cytoplasmic for this ribosomal protein)

  • Validate TMA findings on selected whole tissue sections to confirm expression patterns

• Quality control measures:

  • Regularly repeat staining on control TMA slides to ensure consistent antibody performance over time

  • Implement batch controls when staining multiple TMA slides to account for inter-assay variability

  • Consider dual staining with ribosomal markers to confirm specificity in challenging cases

By implementing these methodological approaches, researchers can effectively utilize RPL39 antibodies in TMA applications to investigate expression patterns across large sample cohorts in various pathological conditions.

What novel applications for RPL39 antibodies are emerging in current research?

While the search results don't explicitly detail novel applications, integrating available information with current trends in ribosomal protein research suggests several emerging applications for RPL39 antibodies:

• Single-cell protein analysis: As single-cell techniques continue to advance, RPL39 antibodies may be adapted for use in mass cytometry (CyTOF) or imaging mass cytometry to analyze ribosomal protein expression at the single-cell level. The validation of RPL39 antibodies in flow cytometry applications provides a foundation for these advanced single-cell approaches.

• Spatial transcriptomics integration: Combining immunofluorescence using RPL39 antibodies (dilution 1:200-1:800) with spatial transcriptomics could reveal correlations between RPL39 protein localization and local mRNA translation patterns in tissue contexts, particularly in disease states.

• Ribosome heterogeneity studies: Recent research has highlighted the existence of specialized ribosomes with distinct compositions and functions. RPL39 antibodies could be employed in immunoprecipitation of intact ribosomes followed by mass spectrometry to investigate ribosome heterogeneity across different cellular contexts.

• Liquid biopsy applications: The detection of circulating ribosomal proteins as potential biomarkers is an emerging area. The validated specificity of RPL39 antibodies could enable the development of sensitive assays for detecting RPL39 in biological fluids.

• CRISPR screening visualization: As multiple publications have used RPL39 antibodies in knockdown/knockout contexts , these antibodies could be valuable for visualizing and validating CRISPR screen hits related to ribosomal biology and translation regulation.

• Proximity labeling approaches: RPL39 antibodies could be adapted for use in proximity labeling techniques (BioID, APEX) to map the spatial interactome of RPL39 and identify novel interacting partners in different cellular compartments.

For researchers interested in these emerging applications, it is advisable to first validate the selected RPL39 antibody in conventional applications (WB, IHC, IF) using recommended positive controls (HepG2 cells, human liver tissue) before adapting protocols for novel methodologies.

How might RPL39 antibodies contribute to our understanding of specialized ribosomes in disease contexts?

The concept of specialized ribosomes—ribosomes with distinct compositions that preferentially translate specific mRNAs—represents a paradigm shift in our understanding of translational control. RPL39 antibodies can serve as valuable tools for investigating this emerging field, particularly in disease contexts:

• Ribosome immunoprecipitation studies: RPL39 antibodies validated for immunoprecipitation applications can be used to isolate RPL39-containing ribosomes, followed by RNA sequencing of associated mRNAs (RIP-seq). This approach could reveal whether RPL39-containing ribosomes preferentially translate specific mRNA subsets in normal versus disease states.

• Tissue-specific expression analysis: Using the validated immunohistochemistry applications of RPL39 antibodies (14990-1-AP, A10219-1, A10219S39) , researchers can map RPL39 expression across different tissues and disease states. The confirmed reactivity in human liver cancer tissue and colorectal carcinoma provides a starting point for investigating cancer-specific patterns.

• Co-localization with specialized translation factors: Immunofluorescence applications using RPL39 antibodies (dilution 1:200-1:800) can be combined with markers of specialized translation (such as stress granule components or initiation factors) to investigate whether RPL39-containing ribosomes participate in distinct translational programs under stress or disease conditions.

• Quantitative proteomics of disease ribosomes: RPL39 antibodies can facilitate the purification of ribosomes from disease models or patient samples for subsequent quantitative proteomic analysis, revealing disease-specific alterations in ribosome composition that might include changes in RPL39 incorporation.

• Genetic manipulation studies: The validated use of RPL39 antibodies in knockdown/knockout contexts enables researchers to investigate how modulating RPL39 levels affects the translation of specific mRNAs involved in disease progression, potentially revealing specialized functions beyond its structural role in ribosomes.

By implementing these approaches, researchers can leverage RPL39 antibodies to expand our understanding of how specialized ribosomes may contribute to disease pathogenesis, potentially identifying novel therapeutic targets aimed at modulating specific translational programs rather than global protein synthesis.

What are the key publications that have utilized RPL39 antibodies in their research methodologies?

According to the search results, multiple publications have successfully utilized RPL39 antibodies across various experimental applications:

While the search results do not provide the specific citation information for these publications, researchers interested in examining the methodological details of these studies can:

• Contact the antibody manufacturers (Proteintech for 14990-1-AP, Boster Bio for A10219-1 and A10219S39) for a list of publications citing their products

• Conduct literature searches using the antibody catalog numbers as search terms

• Review the validation data galleries available on the manufacturer websites, which frequently include representative images from publications